Abstract:Background: Major depressive disorder (MDD) is a type of emotional dysfunction, and its pathogenesis has not been fully elucidated. Specifically, the key molecules in depression-related brain regions involved in this disease and their contributions to this disease are currently unclear. Methods: GSE53987 and GSE54568 were selected from the Gene Expression Omnibus database. The data were standardized to identify the common differentially expressed genes (DEGs) in the cortex of MDD patients in the 2 datasets. The DEGs were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. The STRING database was used to build protein-protein interaction networks, and the cytoHubba plugin was used to identify hub genes. Furthermore, we selected another blood transcriptome dataset that included 161 MDD and 169 control samples to explore the changes in the screened hub genes. Mice were subjected to 4 weeks of chronic unpredictable mild stress to establish an animal model of depression, and the expression of these hub genes in tissues of the prefrontal cortex was then detected by quantitative real time polymerase chain reaction (qRT-PCR). We subsequently predicted the possible posttranscriptional regulatory networks and traditional Chinese medicine according to the hub genes using a few online databases. Results: The analysis identified 147 upregulated genes and 402 downregulated genes were identified in the cortex of MDD patients compared with that of the controls. Enrichment analyses revealed that DEGs were predominantly enriched in synapse-related cell functions, linoleic acid metabolism, and other pathways. Protein-protein interaction analysis identified 20 hub genes based on the total score. The changes in KDM6B, CUX2, NAAA, PHKB, NFYA, GTF2H1, CRK, CCNG2, ACER3, and SLC4A2 in the peripheral blood of MDD patients were consistent with those in the brain. Furthermore, the prefrontal cortex of mice with depressive-like behaviors showed significantly increased Kdm6b, Aridb1, Scaf11, and Thoc2 expression and decreased Ccng2 expression compared with that of normal mice, which was consistent with the results found for the human brain. Potential therapeutic candidates, such as citron, fructus citri, leaves of Panax Notoginseng, sanchi flower, pseudoginseng, and dan-shen root, were selected via traditional Chinese medicine screening. Conclusions: This study identified several novel hub genes in specific brain regions involved in the pathogenesis of MDD, which may not only deepen our understanding of depression but may also provide new ideas for its diagnosis and treatment.

A Study of N-methyl-D-aspartate Receptor Gene (GRIN2B) Variants As Predictors of Treatment-Resistant Major Depression

Significant Linkage and Association Between a Functional (gt)n Polymorphism in Promoter of the N-methyl-D-aspartate Receptor Subunit Gene (GRIN2A) and Schizophrenia.

Targeting of NMDA Receptors in the Treatment of Major Depression.

Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors

The Role of BDNF, NTRK2 Gene and Their Interaction in Development of Treatment-Resistant Depression: Data from Multicenter, Prospective, Longitudinal Clinic Practice

Significant Association Between the Genetic Variations in the 5′ End of the N-Methyl-D-Aspartate Receptor Subunit Gene GRIN1 and Schizophrenia

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

De Novo Mutations and Rare Variants Occurring in NMDA Receptors.

An Association Study of the N-Methyl-D-Aspartate Receptor Nr1 Subunit Gene (grin1) and Nr2b Subunit Gene (grin2b) in Schizophrenia with Universal Dna Microarray

Association study between the NMDA receptor 2B subunit gene ( GRIN2B ) and schizophrenia: A HuGE review and meta-analysis

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

Heterogeneous Clinical and Functional Features of GRIN2D-related Developmental and Epileptic Encephalopathy.

Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression

Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology

Combining bioinformatics, network pharmacology and artificial intelligence to predict the target genes of S-ketamine for treating major depressive disorder

Prediction of repeated-dose intravenous ketamine response in major depressive disorder using the GWAS-based machine learning approach.

GluN2A: A Promising Target for Developing Novel Antidepressants

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Key Risk Genes Identified From the Postmortem Brain of Patients With Major Depressive Disorder and Their Potential Clinical Applications